Scott Power: ASX health lifts to start FY26, Tetratherix ends IPO drought
Wound management house Tetratherix make its ASX debut and breaks an IPO drought for sector
ProMedicus surges past $300 for first time following two new US customer contracts worth a total $190 million
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick.
Morgans' senior healthcare analyst Scott Power has started FY26 in an optimistic mood, noting that despite the global geopolitical and economic uncertainties of recent months, the market broadly has been powering through and hitting new highs across many sectors.
He noted healthcare was the laggard, with the S&P/ASX 200 Health Care Index falling 1.05% in June and down 6.64% YTD but said there was money flowing into the market more broadly.
"If you look across the market there's multiple capital raisings going on across different sectors," he said.
"That is suggesting people are feeling more confident and putting money to work."
Wound management house Tetratherix (ASX:TTX) made its ASX debut on Monday breaking an IPO drought for the sector and trading up to 13% above their $2.88 a share offer price.
Tetratherix is the first life sciences IPO since late November 2024, when cryogenics play Vitrafy Life Sciences (ASX:VFY) and nerve repair house ReNerve (ASX:RNV) listed on the same day.
Barrenjoey Markets and Morgans Financial were joint lead managers and underwriters to the Tetratherix IPO.
The S&P/ASX 200 Health Care index (ASX:XHJ) was up 1.6% for the past five days, while the benchmark S&P/ASX 200 (ASX:XJO) rose 0.6% for the past five days.
"Over the past couple of months it has been pretty downbeat but it certainly feels a lot more upbeat, particularly since the end of the financial year and all the tax loss selling out of the way," Power said.
ProMedicus surges past $300 on contract wins
Health imaging stock ProMedicus (ASX:PME) surged ~10% on Thursday to rocket past $300 for the first time after announcing two new US customer contracts worth a total $190 million.
The first win is a $170 million, 10-year contract with Colorado-based UCHealth, for the company's suite of image viewing and storage tools.
The deal expands Promedicus into cardiology imaging, one of the adjacent 'ologies' the company had been targeting.
UCHealth is a Colorado-based network of 14 hospitals, with affiliate clinics extending into Wyoming and Nebraska.
Louisiana-based Franciscan Missionaries of Our Lady Health also renewed an existing contract for $20m, over five years.
The deal renews a contract for the company's Visage 7 viewer, at a higher per-transaction fee. It also provides the merciful missionaries with Visage 7 Open Archive, which offers 'best-in-class interoperability'.
The UCHealth contract is ProMedicus' largest deal to date and follows a $330m, 10-year agreement signed in November with Trinity Health, one of the largest not-for-profit healthcare systems in the US.
"This company just goes from strength to strength and with the share price currently above $300 it has more than recovered from the wobbles it had in April when US President Donald Trump announced the tariffs," Power said.
Morgans maintains a trim rating on ProMedicus and increased its 12-month target price from $250 to $280.
"We view PME as one of the highest quality businesses on the ASX with high margins and long contracted revenue base, providing significant baseline earnings support," healthcare analyst Iain Wilkie wrote in a note to client.
"We have a DCF valuation of A$280 p/s and with shares trading above this level, we advocate for active investors to TRIM overweight positions."
Power's Powerplay – Micro X pivots to focus on medical applications
Leader in cold cathode x-ray technology for health and security markets Micro-X (ASX:MX1) is Power's pick of the week.
Power said the company had recently raised capital, added a strategic investor and realigned its business to focus on medical imaging, deprioritising security and defence.
He said the realignment made sense and the business was funded to execute on the strategy.
"It's early days in the realignment and customer receipts from imaging are still modest, although a major US hospital is evaluating the Rover+ mobile x-ray unit which could result in material sales over time," he said.
Morgans has a speculative buy rating on Micro X and 12-month target price of 17 cents.
Underperformers selling up assets
Power said there were underperforming companies across the ASX healthcare sector, which were looking to, or have managed to, sell their primary assets.
He said examples were Next Science (ASX:NXS) and MedAdvisor (ASX:MDR).
Next Science has entered a binding asset purchase agreement to sell substantially all its assets for US$50m to Demetra, an Italian based healthcare company.
The directors have unanimously recommended shareholders vote in favour of the proposed transaction.
Assuming the transaction is completed at an EGM on August 14 and after repayment of debts and other costs, NXS will distribute remaining funds to shareholders estimated to be US$30m (~15 cents per share).
MedAdvisor has entered into a binding share sale and purchase agreement to sell its ANZ business division and associated intellectual property to Jonas Software AUS Pty Ltd – part of multinational Constellation Software for $35m.
"In both cases from a share price perspective they have significantly underperformed for a long time and the decision has been made, in my opinion correctly, to find a buyer," Power said.
"Albeit, shareholders will have lost money but it's better to at least get something rather than let the value of the business deteriorate more.
"I wouldn't be surprised if there are more companies which follow that path as across the life science sector there has been dozens of companies which have had massive share price underperformance."
EMVision makes progress on key trials
EMvision Medical Devices (ASX:EMV) announced this week five of the six sites were now enrolling and scanning patients in the pivotal validation trial for its first commercial device – the emu point-of-care bedside brain scanner for stroke diagnosis.
EMVision said the site initiation visit and device training at the third US site for the pivotal trial – designed to support US Food and Drug Administration (FDA) de novo (new device) clearance for emu – at the Mount Sinai site in New York was a success, with recruitment underway.
The sixth and final site, on the west coast of the US, for the pivotal trial is expected to be announced shortly. The trial has an estimated enrolment period of 6-12 months, followed by analysis and reporting of the clinical data.
EMVision said in parallel it was also undertaking cost-effective strategy for continued device innovation, algorithm enhancement and data to support indication expansion to traumatic brain injury.
Referred to as EMVision's Continuous Innovation Study the initiative has received ethics approval received to start scanning patients with suspected stroke or traumatic brain injury at Brisbane's Princess Alexandra Hospital and John Hunter Hospital in Newcastle shortly.
"EMVision is making good progress," Power said.
Neurizon signs global licensing deal with NYSE-listed Elanco
Neurizon Therapeutics (ASX:NUZ) has entered an exclusive global licensing deal with New York Stock Exchange-listed Elanco Animal Health Incorporated and affiliates for monepantel, the active pharmaceutical ingredient in its lead drug NUZ-001.
Neurizon said the licensing deal strengthen its strategic outlook for development, manufacturing and potential future commercialisation of NUZ-001, which is in development for the most common form of motor neurone disease (MND) called amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
The company said the licensing agreement also strengthens its regulatory position by providing ongoing access to essential animal safety and manufacturing data — both critical pillars for advancing clinical trials, securing potential regulatory approvals, and enabling global market entry.
In a note to client Wilkie said Neurizon was a strong proposition in the rare disease space with significant near-term catalysts in a condensed timeframe and precedent for an accelerated approval pathway.
"While considerable clinical risk remains, we view NUZ-001 as a drug with a sound scientific basis in ALS, strong safety profile, and promising hint of potential efficacy above existing treatments," he wrote.
Morgans has a speculative buy rating on Neurizon and 12-month target price of 42 cents.
The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.
Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
At Stockhead, we tell it like it is. While EMVision and Neurizon are Stockhead advertisers, the companies did not sponsor this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
an hour ago
- SBS Australia
SBS News in Filipino, Saturday 5 July 2025
Philippine Amusement and Gaming Corporation (PAGCOR) welcomes proposals to tighten online gambling rules. Prime Minister Anthony Albanese has outlined his economic agenda in opposition to the U-S Trump Administration, calling for Australia to become a green energy superpower. De La Salle Santiago Zobel (DLSZ) Rondalla to perform at the Australian International Music Festival this July 2025. Pakinggan ang Podcast SBS Filipino 05/07/2025 05:59 Filipino 📢 Where to Catch SBS Filipino
News.com.au
2 hours ago
- News.com.au
Everything we know about Lyssavirus after man dies in state first
A northern NSW man has died after being bitten by a bat, in the first confirmed case of Australian bat lyssavirus (ABLV) in NSW. The man, in his 50s, was bitten by a bat several months ago and had been in a critical condition in hospital, but on Thursday NSW Health confirmed he had died. 'We express our sincere condolences to the man's family and friends for their tragic loss,' NSW Health said in a statement. The case marks the fourth ever documented of ABLV, all have been fatal. What is Lyssavirus? 'ABLV is a virus that circulates naturally in Australian bats that is very closely related to rabies,' said veterinarian and wildlife disease expert Dr Alison Peel. 'To infect a human, the virus needs to pass from the bat's saliva into a wound in the skin. For example, that can happen if an infected bat scratches or bites you, or if their saliva comes into contact with an existing break in your skin. 'You cannot contract the virus just by being near flying foxes.' Once infected the victim will experience a latency period where they are asymptomatic and appear healthy, this period may stretch from weeks to possibly years until symptoms begin to appear. 'Once symptomatic, ABLV infection has a 100 per cent fatality rate with no effective treatment available,' said molecular virologist professor Vinod Balasubramaniam. '(ABLV) infects peripheral nerves and progresses rapidly to the central nervous system, causing fatal acute encephalomyelitis (inflammation of the brain and spinal cord).' ABLV was first identified by the CSIRO in 1996, after a black flying fox exhibiting neurological symptoms was discovered near Ballina in northern New South Wales. Later that same year, a woman in Queensland who had recently begun working as a bat handler developed numbness and weakness in her arm, before falling into a coma and passing away. Two more fatalities occurred in 1998 and 2013, when a woman and an eight-year-old child died after being bitten or scratched by bats. Although the virus is found in Australian bats it exists in an extremely low percentage of the population. Exact numbers are difficult to determine due to its scarcity however Trish Paterson, who ran the Australian Bat Clinic and Wildlife Trauma Centre in Queensland, told the ABC less than 0.1 per cent of the Australian bat population was infected with the virus. 'The virus is present in the saliva of some Australian bats, but at very low prevalence,' said Dr Peel. 'The proportion of bats infected by the virus is normally very low – studies have looked for the virus in thousands of healthy bats and failed to find it. 'Like humans and other animals, infected bats may become sick and die, however, some bats may appear unaffected. So, you can't always tell just by looking at a bat whether it's infected or not.' What can you do to protect yourself? Experts stressed the best defence against ABLV was avoiding bats and particularly avoiding provoking them. 'This recent NSW case, the first in the state, highlights significant lessons for public health: individuals must avoid direct contact with bats,' said professor Balasubramaniam. 'Unvaccinated people should avoid handling bats in the wild, and if they encounter an injured bat they should contact their local wildlife rescue group, rather than trying to handle the animal themselves,' said director of equine infectious diseases at Melbourne University professor James Gilkerson. 'Veterinarians and wildlife carers are two groups at higher risk, and it is recommended that those people are vaccinated against rabies to protect them against ABLV infection.' Professor Balasubramaniam advised those bitten or scratched to 'seek immediate medical intervention, including thorough wound cleaning and prompt administration of rabies immunoglobulin and vaccines following any potential exposure'. 'Public health authorities must adopt a robust approach such as intensifying targeted education for high-risk groups like veterinarians and wildlife handlers, enhancing surveillance of bat populations, and investing in research for advanced vaccines and antiviral therapies. 'The (recent) incident highlights the critical need to respect ecological boundaries, promote community awareness, and ensure swift, evidence-based medical and public health responses.'
News.com.au
2 hours ago
- News.com.au
Ex-senator Helen Kroger, Bob Hawke chief of staff Graham Evans sell
Political heavyweights including former Victorian Liberal Party president and senator Helen Kroger and Bob Hawke's chief of staff Graham Evans are in the midst of real estate moves. It was second-time lucky for Ms Kroger who sold her Hawthorn home for $2.488m recently, after an earlier attempt in spring last year. Holding off helped score a better result for the Australian senator who held office from 2008-2014, who had the three-bedroom, two-bathroom property listed for $2.2m-$2.4m last year. Marshall White's Nicholas Franzmann took over the listing from another agency earlier this year and said the property's size, single-level design, access to transport and a renovation had been key for the young couple and a professional who contested it. While he declined to comment on the vendor, Mr Franzmann said the sale had demonstrated growing buyer confidence. 'We certainly have better connections with people since the two rate drops, so while a few 0.25 per cents is not life changing, it does send a positive message,' he said. Meanwhile, Mr Evans who had a distinguished, 27-year career in the public service that included time as the secretary for the Department of Transport as well as for Department of Primary Industries and Energy, as well as a three-year stint as Mr Hawke's chief of staff. But he said his proudest achievement, which also earned him the accolade of Officer of the order of Australia, was his work in micro-economic reform especially in transport and communications — ultimately paving the way for digital radio and TV as well as for mobile phones to reach their ubiquitous use today. The former public servant is selling the Port Fairy home he's used as a regional base for 17 years. While the local golf links have convinced friends and family to join him and his partner on visits to the property over the years, it's also a convenient walk to most of the towns key features — and neighbours regularly use their private jetties for kayaking and fishing trips. Mr Evans said after growing up in Colac they had bought the Gipps St home in 2008 with past holidays to the coastal town in mind, but had come to love regular music festivals and town events. 'People probably see it as holiday place with a lot of those sort of attractions, but having lived there for a while there are a lot of things that make it a great place,' he said. He said the water views from the spacious living zones of the ground level as well as two of the bedrooms upstairs were a constant hallmark of the home's relaxed lifestyle. Charles Stewart's Penny Adamson said the home was one of only a handful in the town with a lawn stretching all the way to the water and its own jetty. Its relative rarity, open-plan lay out, 575sq m allotment and a build by locally renowned Mick Hearn have enticed interest from buyers including Melburnians looking to relocate, locals looking to downsize, and farmers looking for a town residence. It is listed for sale at $2.8m.
